MARKET

APVO

APVO

Aptevo Therapeutics Inc
NASDAQ
6.90
+0.20
+2.99%
After Hours: 6.90 0 0.00% 16:22 02/09 EST
OPEN
6.84
PREV CLOSE
6.70
HIGH
7.11
LOW
6.66
VOLUME
14.79K
TURNOVER
--
52 WEEK HIGH
1,465.20
52 WEEK LOW
5.94
MARKET CAP
6.89M
P/E (TTM)
-0.0000
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at APVO last week (0202-0206)?
Weekly Report · 22h ago
Aptevo Therapeutics announces CEO transition, board leadership changes
Seeking Alpha · 6d ago
Aptevo Therapeutics Announces CEO Transition and Leadership Changes
TipRanks · 6d ago
Aptevo Therapeutics CEO Marvin White to retire, assume Executive Chair role
TipRanks · 6d ago
APTEVO THERAPEUTICS INC - JEFF LAMOTHE TO BECOME APTEVO CEO; MARVIN WHITE EXECUTIVE CHAIR - SEC FILING
Reuters · 6d ago
APTEVO THERAPEUTICS INC - MARVIN WHITE TO RETIRE AS APTEVO CEO EFFECTIVE APRIL 1, 2026 - SEC FILING
Reuters · 6d ago
Aptevo Therapeutics President, CEO Marvin White To Retire, Effective April 1, Transitioning To Executive Chair; COO Jeff Lamothe Appointed President, CEO
Benzinga · 6d ago
Aptevo Therapeutics ernennt Jeff Lamothe zum neuen CEO
Reuters · 6d ago
More
About APVO
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.

Webull offers Aptevo Therapeutics Inc stock information, including NASDAQ: APVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APVO stock methods without spending real money on the virtual paper trading platform.